SCHEMBL23102124

SCHEMBL23102124

CC(S)N1CCc2cc(Cl)ccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.43
HTR2A P28223 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
KCNH2 Q12809 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
NOTUM Q6P988 2/20 0.39
TRPV3 Q8NET8 1/20 0.38
AKR1C3 P42330 1/20 0.37
AKR1C1 Q04828 1/20 0.37
HRH1 P35367 1/20 0.36
HSD17B3 P37058 2/20 0.35
OGA O60502 1/20 0.35
DRD2 P14416 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21361477 0.87 HTR2A (0.44) ACACBHTR2AHTR2CHTR2BKCNH2
SCHEMBL23102118 0.81 ACACB (0.44) ACACBHTR2AHTR2CHTR2BKCNH2
SCHEMBL22400018 0.81 OGA (0.41) ACACBHTR2AHTR2COGAKDM4E
SCHEMBL9963388 0.80 ASIC3 (0.48) ACACBHTR2AHTR2CHTR2BKCNH2
SCHEMBL22879105 0.78 MAOA (0.53) HTR2AHTR2BNOTUMHRH1OGA
SCHEMBL23102156 0.77 DRD2 (0.52) HTR2AHTR2CAKR1C3AKR1C1DRD2
SCHEMBL20665096 0.75 TMEM97 (0.47) ACACBHTR2AHTR2CHTR2BKCNH2
SCHEMBL10311216 0.75 HTR2A (0.43) ACACBHTR2AHTR2CHTR2BKCNH2
SCHEMBL2632898 0.75 HTR2A (0.43) ACACBHTR2AHTR2CHTR2BKCNH2
SCHEMBL6883015 0.74 MAOA (0.59) HTR2AHTR2CHTR2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G ACACB 2712/4885HTR2A 4254/4885HTR2C 4577/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ACACB 2741/4885HTR2A 4166/4885HTR2C 4504/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ACACB 2988/4885HTR2A 4157/4885HTR2C 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.